Member Info for Babbler2

Of course if they have a good opportunity that requires immediate extra cash then maybe... but that would be a good thing...perhaps why its been held. Lets see...

they have �20m cash and grants / joint funding ... so imo no placing needed this year no?

It dropped... as 70% is owned by IIs... so very illiquid and that distressed seller 2 weeks ago killed it... imo. Only 30% free-float last report on their site... selling seems to have dried up yesterday... lets see... Too UTR here so relies on MM games :(

ta - seems good to me - with new management and direction looks interesting. Note the INFA rns too: Finalisation of formal contract agreements with key FEED contractors is nearing completion and FEED commencement is expected to be announced shortly; and The Board is assessing opportunities for additional grant funding and believes, based on work undertaken, there is potential for a 40 year operational life compared to the 20 year life upon which the Project economics have been modelled to date; Detailed discussions continue with construction financing providers in respect of Project level finance. A number of providers have expressed a conditional interest in taking a substantial Project level equity stake in Islandmagee's construction financing, subject to completion of due diligence and terms being agreed. Lots of interest there it seems... once placing shares clear?

She obviously wasn't "liked" by the market going by the price reaction imo... lets see though right?

Boom - lol - was going to sell but might consider a hold now... see how price reacts of course!

2ND RNS - needs new blood to drive the price back up imo: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development and drug discovery services business, announces that Kym Denny is stepping down as Chief Executive of the Company with immediate effect. Trevor Phillips, Executive Chairman, will take over Kym's responsibilities. Trevor Phillips, Executive Chairman of hVIVO plc said: "We would like to thank Kym for her contribution to the Group and wish her well for the future."

"2017 has been a productive year for hVIVO, during which we expanded our services with new proprietary precision development service following the integration of our human disease clinical trial platform and our insights into the biology of diseases that impact the airways. These biological insights played a vital role in advancing the universal flu vaccine candidate FLU-v, where, post period, we announced encouraging symptom based results. This vaccine candidate is designed to minimise the impact of the virus by reducing symptoms - potentially relegating flu to a much milder disease - through stimulating an immune response, in contrast to seasonal flu vaccines. We believe this is the first time any universal flu vaccine candidate has demonstrated a statistically significant reduction in a symptom measure for flu in humans in a controlled clinical study. Our know-how and expertise has also enabled us to expand into new areas, such as drug target identification which we will leverage within our services offering. We look forward with confidence to 2018, building on our position as an industry leader in human challenge studies and to expand further into areas such as asthma. Our expanded clinical services platform and precision development services approach has already generated significant interest from global pharmaceutical companies and we are excited about the opportunities."

Achieved efficiencies in hVIVO's operations to maximise cash reserves and prioritise investment spend to achieve near term value inflection milestones: o hVIVO finished the year with revenue and gross margin in line with market expectations for 2017, while year-end cash was markedly ahead.

Results out... I like this: this study demonstrated a statistically significant reduction in a symptom measure for flu in humans in a controlled clinical study. We believe this is the first time that any universal flu vaccine candidate has demonstrated successful symptom-based results.

Morning. I listened - but no funds to do anything lol... Hoping to see a spike in HVO today - only news Im interested in! Want to take it into MWG asap if possible... Hope all are well.

shhhhh... keep it to yourselves ;)

Most "unknown" share price rises are down to funding... seems a lot still don't know that... imo. Nice if you get in "on the know" of course... nah that cant happen... can it?? ;)

Boom tomorrow!! lol.

as I said this morning... the V heading back to 14p... hmmm... hey ho.

hmmm... really frustrating when all my other watch list is rising and opportunities disappearing lol. Hope it more than makes up for it tomorrow (ie 30p plus). Controlled here for some reason though :(

Last day to get in before results... will it rise? Will there be a spike tomorrow? Who knows... but there damn well should be ;)

Finally take a look into tef...

So... will there be a build up in the share price of N4P leading up to results in august...?

yep... the mind boggles right... or did they? Its AIM - do you need proof of such dealings? What will the FSA do? NADA.